<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893057</url>
  </required_header>
  <id_info>
    <org_study_id>2021/601</org_study_id>
    <nct_id>NCT04893057</nct_id>
  </id_info>
  <brief_title>SARS-CoV2 Seroprevalence in Pregnant Women and Blood Donors</brief_title>
  <acronym>CoVERED</acronym>
  <official_title>SARS-CoV2 sERoprévalences Dans la Population Des Femmes Enceintes et Donneurs de Sang</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with&#xD;
      antibodies against the virus) in pregnant women and blood donors in an administrative area of&#xD;
      France, and to determine whether these measures are representative of the general population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-SARS-CoV-2 spike protein total IgG</measure>
    <time_frame>at inclusion</time_frame>
    <description>Total IgG directed against anti-SARS-CoV-2 spike protein as measured by ELISA assay</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>COVID-19 Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Pregnant women</arm_group_label>
    <description>Women admitted to hospital for a live birth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood donors</arm_group_label>
    <description>Subjects qualified for whole blood donation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult pregnant women and adult blood donors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
               -  Adult female&#xD;
&#xD;
               -  Admitted to hospital for live birth&#xD;
&#xD;
               -  Informed consent&#xD;
&#xD;
               -  Affiliated to the French social security health insurance scheme&#xD;
&#xD;
          -  Blood donors&#xD;
&#xD;
               -  Adult male or female&#xD;
&#xD;
               -  Qualified for whole blood donation (up to 70 years old in France)&#xD;
&#xD;
               -  Informed consent&#xD;
&#xD;
               -  Affiliated to the French social security health insurance scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Subject without health insurance coverage&#xD;
&#xD;
          -  Exclusion period of another study or exclusion period of the French national healthy&#xD;
             volunteer registry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime Desmarets, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noémie Nminej</last_name>
    <phone>+333 81 21 85 18</phone>
    <email>nmninej@chu-besancon.fr</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

